What is polatuzumab used for?
Polatuzumab is used to treat a certain type of lymphoma (diffuse large B-cell lymphoma, also known as DLBCL). This medication works by stopping the growth of cancer cells.
Is polatuzumab chemo?
The targeted drug finds the cancer cell and then delivers the chemo to destroy it. In this case, Polivy attaches to a specific protein found on B cells in people with lymphoma, then releases its chemotherapy into those cells to kill the cancer.
Is polatuzumab vedotin immunotherapy?
Polatuzumab vedotin, a targeted immunotherapy, was approved in 2019 by the U.S. Food & Drug Administration for the treatment of relapsed/refractory diffuse large B-cell lymphoma and is recommended by the National Comprehensive Cancer Network for patients who are transplant ineligible.
Is polatuzumab a monoclonal antibody?
Polatuzumab vedotin is an antibody-drug conjugate composed of a humanized monoclonal antibody (mAb) targeting B-cell antigen receptor complex-associated protein beta chain (CD79b) and a microtubule-disrupting toxin, monomethyl auristatin E (MMAE).
How is Polatuzumab given?
Polatuzumab vedotin-piiq is given by IV (into a vein) infusion. The dose is based on a combination of your height and weight and how often you receive the medication will be decided by your care team.
When was polivy FDA approved?
Development Timeline for Polivy
| Date | Article |
|---|---|
| Jun 10, 2019 | Approval FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma |
Is bendamustine a chemo?
Generic Name: bendamustine This medication is used to treat certain types of cancer (such as lymphoma, chronic lymphocytic leukemia – CLL). Bendamustine belongs to a class of cancer chemotherapy drugs known as alkylating agents. It works by killing cancer cells or slowing their growth.